- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01357993
A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
27. mars 2014 oppdatert av: Janssen Pharmaceutical K.K.
An Open-Label, Dose-Titration, Long-Term Study to Evaluate the Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg or 72 mg Per Day
The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at 18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Detaljert beskrivelse
This is a multicenter, open-label (all people involved know the identity of the intervention), dose-titration (to adjust the dose of a drug until optimal result is reached), long-term safety study in adult patients with a diagnosis of ADHD.
The study consists of the Long-term phase (4-week titration period and 44-week maintenance period) and the 1-week Post-study phase.
The 4 week-titration period is to find the individualized dose for each patient regardless of the treatments in the preceding study (JNS001-JPN-A01).
Patients will be titrated from a starting dose of 18 mg/day for 7 days, and continue with a weekly (+/- 2 days) increment of 9 or 18 mg until an individualized dose is achieved.
The titration period will be followed by a 44-week maintenance period which has combined 48-week (1-year) treatment duration with the titration period.
During the maintenance period, the dose will be adjusted between 18 to 72 mg depending on the patients' symptoms.
In the post-study phase, safety information will be collected after the last dose of the study treatment or premature discontinuation.
The study drug will be administered with water once daily in the morning at doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg, or 72 mg per day.
The study treatment period is 48 weeks (titration period of 4 weeks and maintenance period of 44 weeks).
Studietype
Intervensjonell
Registrering (Faktiske)
253
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Chiba, Japan
-
Chigasaki, Japan
-
Chiyoda, Japan
-
Fuchu, Japan
-
Fukuoka, Japan
-
Fukushima, Japan
-
Hamamatsu, Japan
-
Higashi-Osaka, Japan
-
Ichikawa, Japan
-
Iruma, Japan
-
Isehara, Japan
-
Kashihara, Japan
-
Kishiwada, Japan
-
Kobe, Japan
-
Kumamoto, Japan
-
Kurume, Japan
-
Matsuyama, Japan
-
Nagasaki, Japan
-
Nagoya, Japan
-
Nara, Japan
-
Neyagawa, Japan
-
Osaka, Japan
-
Saitama, Japan
-
Sakai, Japan
-
Sapporo, Japan
-
Shibuya, Japan
-
Takatsuki, Japan
-
Tokyo, Japan
-
Yokohama, Japan
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patients (and their legally-acceptable representative if patients are 18 or 19 years old) must have signed an Informed Consent Form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
- Patients who completed the preceding study (JNS001-JPN-A01), are considered to be appropriate to continue JNS001 treatment into this extension study by investigator or subinvestigator
- Women of childbearing potential must have a negative urine pregnancy test at the final assessment in the preceding study. If sexually active, continue to use an effective method of birth control throughout the study
- Men must agree to use a double-barrier method of birth control and not donate sperm during the study and for 90 days after receiving the last dose of study drug.
Exclusion Criteria:
- Patients who have reported AEs which would prevent transfer to this study from the preceding study (JNS001-JPN-A01)
- Patients who had been judged ineligible as patients for this study by investigator or subinvestigator
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: 001
JNS001 18 mg 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
|
18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Tidsramme: Throughout the study period (Month 12)
|
Throughout the study period (Month 12)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change in DSM-IV Total ADHD symptoms scores (18 items) of the investigator-rated CAARS-O: SV from baseline of the preceding study (JNS001-JPN-A01) to each visit and to endpoint
Tidsramme: Baseline to titration visits (Week 1-4) and to months 2-12 or discontinuation
|
Baseline to titration visits (Week 1-4) and to months 2-12 or discontinuation
|
Change in the scores of the CAARS-S: SV from baseline of the preceding study to each visit and to endpoint
Tidsramme: Baseline to months 1-12 or discontinuation
|
Baseline to months 1-12 or discontinuation
|
Change in the scores of the CGI-S from baseline of the preceding study in the scores of the CGI-S at each visit and endpoint
Tidsramme: Baseline to titration visits (Week 1-4) and to months 2-12 or discontinuation
|
Baseline to titration visits (Week 1-4) and to months 2-12 or discontinuation
|
Change in total score of Q-LES-Q-SF from baseline of the preceding study in the scores of the Q-LES-Q-SFat each visit and endpoint
Tidsramme: Baseline to months 1-12 or discontinuation
|
Baseline to months 1-12 or discontinuation
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2011
Primær fullføring (Faktiske)
1. mars 2013
Studiet fullført (Faktiske)
1. mars 2013
Datoer for studieregistrering
Først innsendt
19. mai 2011
Først innsendt som oppfylte QC-kriteriene
19. mai 2011
Først lagt ut (Anslag)
23. mai 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
28. mars 2014
Siste oppdatering sendt inn som oppfylte QC-kriteriene
27. mars 2014
Sist bekreftet
1. mars 2014
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CR017758
- JNS001-JPN-A02 (Annen identifikator: Janssen Pharmaceutical K.K., Japan)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Attention-Deficit / Hyperactivity Disorder
-
The Hospital for Sick ChildrenEhave; Ontario Brain InstituteFullførtAttention-deficit hyperactivity disorderCanada
-
National Taiwan University HospitalFullførtAttention-deficit/Hyperactivity Disorder
-
National Taiwan University HospitalFullførtAttention-deficit/Hyperactivity DisorderTaiwan
-
University of British ColumbiaUBC Human Early Learning Partnership (HELP)Avsluttet
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)RekrutteringAttention-Deficit Hyperactivity DisorderForente stater
-
Ironshore Pharmaceuticals and Development, IncFullførtAttention-Deficit Hyperactivity DisorderForente stater
-
Florida International UniversityFullførtAttention-deficit/Hyperactivity DisorderForente stater
-
National Taiwan University HospitalFullførtAttention-deficit/Hyperactivity DisorderTaiwan
-
Eli Lilly and CompanyFullførtAttention-Deficit/Hyperactivity DisorderForente stater
-
NYU Langone HealthCorium, Inc.RekrutteringAdult Attention Deficit Hyperactivity DisorderForente stater
Kliniske studier på JNS001
-
Janssen Pharmaceutical K.K.FullførtAttention-Deficit Hyperactivity DisorderJapan